# A Long Term Study to Assess the Safety of Fostamatinib in Patients in Asia With Rheumatoid Arthritis

> **NCT01640054** · PHASE2 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 115 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Fostamatinib

## Key facts

- **NCT ID:** NCT01640054
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-07
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 115 (ACTUAL)
- **Why stopped:** AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to Rigel Pharmaceuticals.
- **Last updated:** 2014-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01640054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01640054, "A Long Term Study to Assess the Safety of Fostamatinib in Patients in Asia With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01640054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*